Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT03299244 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03299244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03299244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2018
Completion date
April 8, 2020
Enrollment
637 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, secondary hyperparathyroidism